PMS-CANDESARTAN TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
12-10-2016
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CANDESARTAN CILEXETIL
제공처:
PHARMASCIENCE INC
ATC 코드:
C09CA06
INN (International Name):
CANDESARTAN
복용량:
32MG
약제 형태:
TABLET
구성:
CANDESARTAN CILEXETIL 32MG
관리 경로:
ORAL
패키지 단위:
30/100
처방전 유형:
Prescription
치료 영역:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
제품 요약:
Active ingredient group (AIG) number: 0135220004; AHFS:
승인 상태:
APPROVED
승인 날짜:
2012-08-03
제품 특성 요약
_pms-CANDESARTAN Product Monograph_
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
PMS-CANDESARTAN
Candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
PHARMASCIENCE INC.
6111 Av. Royalmount, Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
JULY 19, 2016
Submission Control No: 195306
_pms-CANDESARTAN Product Monograph_
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND
ADMINISTRATION..............................................................................
16
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
.........................................................................................................
24
전체 문서 읽기
